PURPOSE: Multivariate prognostic instruments aim to predict risk of recurrence among patients with localized prostate cancer. We devised a novel risk assessment tool which would be a strong predictor of outcome across various levels of risk, and which could be easily applied and intuitively understood. MATERIALS AND METHODS: We studied 1,439 men diagnosed between 1992 and 2001 who had undergone radical prostatectomy and were followed in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database, a longitudinal, community based disease registry of patients with prostate cancer. Disease recurrence was defined as prostate specific antigen (PSA) 0.2 ng/ml or greater on 2 consecutive occasions following prostatectomy or a second cancer treatment more than 6 months after surgery. The University of California, San Francisco-Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score was developed using preoperative PSA, Gleason score, clinical T stage, biopsy results and age. The index was developed and validated using Cox proportional hazards and life table analyses. RESULTS: A total of 210 patients (15%) had recurrence, 145 by PSA criteria and 65 by second treatment. Based on the results of the Cox analysis, points were assigned based on PSA (0 to 4 points), Gleason score (0 to 3), T stage (0 to 1), age (0 to 1) and percent of biopsy positive cores (0 to 1). The UCSF-CAPRA score range is 0 to 10, with roughly double the risk of recurrence for each 2-point increase in score. Recurrence-free survival at 5 years ranged from 85% for a UCSF-CAPRA score of 0 to 1 (95% CI 73%-92%) to 8% for a score of 7 to 10 (95% CI 0%-28%). The concordance index for the UCSF-CAPRA score was 0.66. CONCLUSIONS: The UCSF-CAPRA score is a straightforward yet powerful preoperative risk assessment tool. It must be externally validated in future studies.
PURPOSE: Multivariate prognostic instruments aim to predict risk of recurrence among patients with localized prostate cancer. We devised a novel risk assessment tool which would be a strong predictor of outcome across various levels of risk, and which could be easily applied and intuitively understood. MATERIALS AND METHODS: We studied 1,439 men diagnosed between 1992 and 2001 who had undergone radical prostatectomy and were followed in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database, a longitudinal, community based disease registry of patients with prostate cancer. Disease recurrence was defined as prostate specific antigen (PSA) 0.2 ng/ml or greater on 2 consecutive occasions following prostatectomy or a second cancer treatment more than 6 months after surgery. The University of California, San Francisco-Cancer of the Prostate Risk Assessment (UCSF-CAPRA) score was developed using preoperative PSA, Gleason score, clinical T stage, biopsy results and age. The index was developed and validated using Cox proportional hazards and life table analyses. RESULTS: A total of 210 patients (15%) had recurrence, 145 by PSA criteria and 65 by second treatment. Based on the results of the Cox analysis, points were assigned based on PSA (0 to 4 points), Gleason score (0 to 3), T stage (0 to 1), age (0 to 1) and percent of biopsy positive cores (0 to 1). The UCSF-CAPRA score range is 0 to 10, with roughly double the risk of recurrence for each 2-point increase in score. Recurrence-free survival at 5 years ranged from 85% for a UCSF-CAPRA score of 0 to 1 (95% CI 73%-92%) to 8% for a score of 7 to 10 (95% CI 0%-28%). The concordance index for the UCSF-CAPRA score was 0.66. CONCLUSIONS: The UCSF-CAPRA score is a straightforward yet powerful preoperative risk assessment tool. It must be externally validated in future studies.
Authors: Stephen J Freedland; William J Aronson; George S Csathy; Christopher J Kane; Christopher L Amling; Joseph C Presti; Frederick Dorey; Martha K Terris Journal: Urology Date: 2003-04 Impact factor: 2.649
Authors: John T Wei; Rodney L Dunn; Howard M Sandler; P William McLaughlin; James E Montie; Mark S Litwin; Linda Nyquist; Martin G Sanda Journal: J Clin Oncol Date: 2002-01-15 Impact factor: 44.544
Authors: Gary D Grossfeld; David M Latini; Deborah P Lubeck; Jeanette M Broering; Yu Ping Li; Shilpa S Mehta; Peter R Carroll Journal: Urology Date: 2002-04 Impact factor: 2.649
Authors: Lars Holmberg; Anna Bill-Axelson; Fred Helgesen; Jaakko O Salo; Per Folmerz; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Christer Busch; Steg Nordling; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson; Bo Johan Norlén Journal: N Engl J Med Date: 2002-09-12 Impact factor: 91.245
Authors: Markus Graefen; Makoto Ohori; Pierre I Karakiewicz; Ilias Cagiannos; Peter G Hammerer; Alexander Haese; Andreas Erbersdobler; Rolf-Peter Henke; Hartwig Huland; Thomas M Wheeler; Kevin Slawin; Peter T Scardino; Michael W Kattan Journal: J Urol Date: 2004-01 Impact factor: 7.450
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: Matthew R Cooperberg; Jeanette M Broering; Mark S Litwin; Deborah P Lubeck; Shilpa S Mehta; James M Henning; Peter R Carroll Journal: J Urol Date: 2004-04 Impact factor: 7.450
Authors: Matthew S Katz; Jason A Efstathiou; Anthony V D'Amico; Michael W Kattan; Martin G Sanda; Paul L Nguyen; Matthew R Smith; Peter R Carroll; Anthony L Zietman Journal: BJU Int Date: 2010-03-15 Impact factor: 5.588
Authors: Sabine Brookman-May; Matthias May; Wolf-Ferdinand Wieland; Steffen Lebentrau; Sven Gunia; Stefan Koch; Christian Gilfrich; Jan Roigas; Bernd Hoschke; Maximilian Burger Journal: World J Urol Date: 2010-12-30 Impact factor: 4.226
Authors: Giovanni Lughezzani; Alberto Briganti; Pierre I Karakiewicz; Michael W Kattan; Francesco Montorsi; Shahrokh F Shariat; Andrew J Vickers Journal: Eur Urol Date: 2010-08-06 Impact factor: 20.096
Authors: David Tiberi; George Rodrigues; Tom Pickles; Jim Morris; Juanita Crook; Andre-Guy Martin; Fabio Cury; Charles Catton; Himu Lukka; Andrew Warner; Daniel Taussky Journal: Can Urol Assoc J Date: 2017 Mar-Apr Impact factor: 1.862
Authors: Hao G Nguyen; Crystal S Conn; Yae Kye; Lingru Xue; Craig M Forester; Janet E Cowan; Andrew C Hsieh; John T Cunningham; Charles Truillet; Feven Tameire; Michael J Evans; Christopher P Evans; Joy C Yang; Byron Hann; Constantinos Koumenis; Peter Walter; Peter R Carroll; Davide Ruggero Journal: Sci Transl Med Date: 2018-05-02 Impact factor: 17.956
Authors: S P Porten; A Smith; A Y Odisho; M S Litwin; C S Saigal; P R Carroll; M R Cooperberg Journal: Prostate Cancer Prostatic Dis Date: 2014-05-13 Impact factor: 5.554
Authors: Zachary Klaassen; Abhay A Singh; Lauren E Howard; Zhaoyong Feng; Bruce Trock; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Christopher J Kane; Alan Partin; Misop Han; Stephen J Freedland Journal: Cancer Date: 2014-12-09 Impact factor: 6.860
Authors: Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino Journal: Future Oncol Date: 2009-12 Impact factor: 3.404